The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| HTFL | N/A | N/A | N/A | +4% |
| S&P | +14.78% | +87.14% | +13.33% | +8% |
HeartFlow, Inc. operates as a cardiovascular company which engages in diagnosing coronary artery diseases. The firm provides a patient-specific analysis of coronary blood flow utilizing coronary CT scans and proprietary computer algorithms based on computational fluid dynamics. The company was founded by Charles A. Taylor, Nathan M. Wilson, and Christopher K. Zarins in July 2007 and is headquartered in Mountain View, CA.
AI-powered cardiac diagnostics firm HeartFlow reported a recent insider buy, as disclosed in the latest SEC filing.
A key FDA-cleared analysis tool earned professional accolades for its utility.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $46.28M | 0.0% |
| Gross Profit | $35.42M | 0.0% |
| Gross Margin | 76.53% | 0.0% |
| Market Cap | $2.81B | 0.0% |
| Market Cap / Employee | $4.02M | 0.0% |
| Employees | 699 | 0.0% |
| Net Income | -$50,855.00K | 0.0% |
| EBITDA | -$13,011.00K | 0.0% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $291.17M | 0.0% |
| Accounts Receivable | $27.86M | 0.0% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $16.27M | 0.0% |
| Short Term Debt | $5.52M | 0.0% |
| Current | YOY Change | |
|---|---|---|
| Return On Invested Capital | -107.93% | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$4,192.00K | 0.0% |
| Operating Free Cash Flow | -$2,957.00K | 0.0% |
| Metric | Q3 2025 | YoY Change | ||
|---|---|---|---|---|
| Price to Book | -3.14 | - | ||
| Price to Tangible Book Value | -3.14 | - | ||
| Enterprise Value to EBITDA | -195.25 | - | ||
| Total Debt | $203.28M | $205.15M | $21.79M | - |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
